Northland Capital Markets Initiates Coverage On TriSalus Life Sciences with Outperform Rating, Announces Price Target of $12.5

Benzinga · 10/25 16:48
Northland Capital Markets analyst Carl Byrnes initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Outperform rating and announces Price Target of $12.5.